Stem Cell Transplant Offers 15-Year Remission for Severe Autoimmune Disease

In a remarkable medical breakthrough, two individuals suffering from a rare and severe autoimmune disease, neuromyelitis optica spectrum disorder (NMOSD), have achieved sustained remission for over 15 years following an experimental stem-cell transplant. The promising results, published in the journal Med, suggest that this pioneering treatment warrants larger clinical trials, offering a beacon of hope for patients grappling with this debilitating condition. NMOSD is a devastating disease where the immune system mistakenly produces antibodies that attack the spinal cord and the nerve connecting the eye and brain. This leads to severe symptoms such as eye pain, vision loss, vomiting, and weakness or paralysis in the limbs, typically appearing in episodes lasting days or months. While conventional treatments exist to prevent these episodes, they proved ineffective for the two patients in this study, highlighting the urgent need for alternative therapeutic strategies. Following the allogeneic hematopoietic stem-cell transplant, both patients experienced significant improvements. The man regained neurological function, resumed a normal life, and went on to have two children. The woman's ability to use her arms improved considerably, and she no longer requires medication to manage her symptoms. Jiao Jiao Li, a biomedical engineer at the University of Technology Sydney, emphasized the profound impact, stating, "I don't think we can say it's a cure, but then again, it has addressed the problem the disease has caused over this very long period of time." The treatment, known as allogeneic hematopoietic stem-cell transplant, involves collecting donor stem cells from the blood of another person. This procedure has been successfully used to treat certain cancers, sickle-cell disease, and other blood disorders. Massimo Filippi, a neurologist and co-author of the study from IRCCS San Raffaele Hospital in Milan, Italy, and his team confirmed that this marks the first reported use of this specific therapy to treat NMOSD. The man received cells from his sister in 2009, while the woman received cells from an unrelated donor the following year, both through a single infusion. Before the transplant, participants underwent a rigorous preparatory regimen, including chemotherapy drugs (fludarabine and treosulfan) and a monoclonal antibody to eliminate the B cells responsible for producing the harmful antibodies that target the spinal cord and optic nerve. To prevent graft-versus-host disease – a potentially life-threatening complication where donor cells attack the recipient's healthy tissues – the patients also received a short course of antibodies and immunosuppressant drugs. Crucially, neither patient developed NMOSD-associated antibodies, and both developed healthy, functioning immune systems, as reported by the study authors. This allogeneic approach completely replaces the patient's immune system, a key distinction from other versions of stem-cell therapy that merely reset the immune system using a person's own cells. Experts suggest that for autoimmune conditions, a complete replacement might be more effective, particularly if the B cells producing the attacking antibodies are not fully eradicated by other methods. The ability to keep these individuals symptom-free for such an extended period is indeed exciting and underscores the potential transformative power of this advanced medical intervention.